Answers are grounded in this paper and cite their sources.
Individuals with eating disorders are using glucagon‐like peptide‐1 (GLP‐1) receptor agonists at a substantially higher rate than the general population, an analysis of an ongoing cross‐sectional study has concluded. The analysis found a 32.1% lifetime prevalence of GLP‐1 use among adults with an eating disorder.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: